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Background COVID-19 is typically a primary respiratory illness with multisystem involvement. The prevalence and clinical signifi-
cance of cardiovascular and multisystem involvement in COVID-19 remain unclear.
....................................................................................................................................................................................................
Methods This is a prospective, observational, multicentre, longitudinal, cohort study with minimal selection criteria and a near-
consecutive approach to screening. Patients who have received hospital care for COVID-19 will be enrolled within
28 days of discharge. Myocardial injury will be diagnosed according to the peak troponin I in relation to the upper
reference limit (URL, 99th centile) (Abbott Architect troponin I assay; sex-specific URL, male: >34 ng/L; female: >16
ng/L). Multisystem, multimodality imaging will be undertaken during the convalescent phase at 28 days post-discharge
(Visit 2). Imaging of the heart, lung, and kidneys will include multiparametric, stress perfusion, cardiovascular magnetic
resonance imaging, and computed tomography coronary angiography. Health and well-being will be assessed in the
longer term. The primary outcome is the proportion of patients with a diagnosis of myocardial inflammation.
....................................................................................................................................................................................................
Conclusion CISCO-19 will provide detailed insights into cardiovascular and multisystem involvement of COVID-19. Our study
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COVID-19 presents the most significant threat to human health in mod-
ern times.1–4 The severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) infection, which causes COVID-19 illness, is mediated
by tropism for nasopharyngeal and pulmonary epithelial cells.
Cardiovascular complications are common, affecting 1 in 4 patients,
are associated with prior cardiovascular disease, and increase the risk of
death.5–11. Cardiovascular injury may be secondary to inflammation, hyp-
oxia, hypotension, and thrombosis, or, potentially, through virus invasion
of endothelial cells, vascular smooth muscle cells, and pericytes, leading
to vascular injury or dysfunction. This mechanism may then play a pri-
mary role in the development of pathology.11 The angiotensin-
converting enzyme 2 (ACE2) transmembrane receptor, which normally
has protective effects in the cardiovascular system, is also the receptor
which mediates virus transmission in human cells, including in the cardio-
vascular system (Figure 1).12,13
Mechanisms of SARS-CoV-2 tropism for
cardiovascular cells
Coronavirus (Coronaviridae family) is named after the crown morphol-
ogy of its outer membrane. SARS-CoV-1, which caused an epidemic in
2002–2003, and SARS-CoV-2, infect human cells when the surface spike
(S) protein, a type 1 membrane glycoprotein,10,12 binds to the ACE2
transmembrane receptor protein on human cells. SARS-CoV-1 and
SARS-CoV-2 have 76% similarity in their S proteins. Fusion of the coro-
navirus S protein with the cell surface ACE2 transmembrane receptor
internalizes the virus, promulgating replication and dissemination. ACE2
is expressed in endothelial cells in the heart, lungs, kidneys, intestine, and
testis,14–16 and is a member of the counter-regulatory axis of the renin–
angiotensin–aldosterone system (RAAS).17 In its canonical function, as a
carboxypeptidase, ACE2 is protective in the cardiovascular system
through its role in metabolising angiotensin I (Ang I) to Ang-(1-9) and
Ang II to Ang-(1-7), therefore reducing Ang II levels and generating the
protective peptides Ang-(1-9) and Ang-(1-7) which act through the
angiotensin type 2 receptor (AT2R)18,19 and the Mas receptor,20
respectively.
Prior knowledge from SARS-CoV and
cardiovascular involvement
Like SARS-CoV-2, SARS-CoV-1 also uses ACE2 and transmembrane
protease serine 2 (TMPRSS2) as mechanisms of cell invasion. During
SARS-CoV-1 infection of transgenic mice expressing human ACE2,
ACE2 becomes dysregulated and depleted.21 In acute lung disease trig-
gered by sepsis, ACE2 is directly protective.22 SARS patients may experi-
ence overwhelming immune and inflammatory responses, in the form of
a cytokine storm, leading to left ventricular (LV) systolic dysfunction,
arrhythmias, and sudden death.23,24 Imaging is therefore well placed to
investigate the underlying pathology of myocardial injury in COVID-19
patients.
Evidence of coronavirus inoculation of
cardiovascular cells and myocarditis
Chan et al.25 provided preliminary evidence of coronavirus infection in
pulmonary endothelial cells. Varga et al. studied the histopathology of
heart, lung, kidney, and liver tissue samples from three patients who died
from COVID-19. They found evidence of viral elements within endothe-
lial cells and endotheliitis.11 Recent studies suggest that systemic
manifestions of COVID-19, including hypertension, thrombosis, myocar-
dial involvement, and kidney failure, may be due to endothelial and vascu-
lar disease.26
High levels of ACE2 are expressed by pericytes in the heart16 and car-
diomyocytes (7.5%, scRNA-seq data).27 ACE2 may have paradoxical
roles since ordinarily it regulates a vasculoprotective signalling pathway
and has protective catalytic effects in the lung. On the other hand, it is a
receptor for virus transmission into human cells. SARS-CoV-2 infection
reduces the activity and/or protein levels of ACE2, leading to a harmful
imbalance of Ang II/AT1R effect.28 ACE2 overexpression enhances the
stability of atherosclerotic plaque.29 However, ACE2 transcript and pro-
tein levels are increased in patients with cardiovascular disease such as
heart failure,16 and post-myocardial infarction (MI),30 implying an in-
creased risk of cardiac infection. The association between COVID-19
and RAAS inhibitor therapy31,32 and other cardiovascular medications21
is most probably explained by underlying cardiovascular disease.31 There
have been a number of case reports or case series of reported COVID-
19-associated myocardial injury, presenting as myocarditis2,5,33,34 or re-
verse Takotsubo.35,36 A number of autopsy reports identify SARS-CoV-
2 RNA in the myocardium of patients dying from COVID-19-related
complications (pulmonary embolism and pneumonitis37, and unde-
fined38), whilst other series do not identify myocardial SARS-CoV-2
RNA in the context of death related to pneumonitis and acute respira-
tory distress syndrome (ARDS).39–42 Taken together, this suggests that
there are several potential mechanisms of myocardial injury (endotypes)
in severe SARS-CoV-2 infection and that further research is warranted.
Evidence of venous and pulmonary arterial
thrombosis
Endothelial damage and thrombotic microvascular angiopathy may
underpin systemic vascular dysfunction.10 Autopsy studies have shown
evidence of this at a pulmonary microvascular level, and this may be
responsible in part for the severe hypoxia present in these patients.43
Evidence of renal involvement
The prevalence of renal involvement in patients with SARS-CoV-2 infec-
tion is low,44,45 and is hypothesized to be secondary to cytokine damage,
systemic effects of the illness,44 or interaction between the cardio-
pulmonary axis and renal function, as has been reported in ARDS.46
Contemporary definitions of acute
myocardial infarction or myocardial
injury
Acute myocardial injury is defined as a rise in the circulating concentra-
tion of troponin above the 99th percentile of the upper reference limit
and then a fall. Acute MI is myocardial injury in the context of myocardial
ischaemia. Acute MI is categorized into one of five types.47 Type 1 MI
is diagnosed based on the occurrence of at least one of the following:
(i) symptoms of acute myocardial ischaemia; (ii) new ischaemic ECG
changes; (iii) development of pathological Q waves; (iv) imaging evidence
of new loss of viable myocardium or new regional wall motion abnor-
mality in a pattern consistent with an ischaemic aetiology; or (v) identifi-
cation of a coronary thrombus by angiography including intracoronary
imaging or by autopsy. Clinical scenarios of Type 1 MI include coronary
plaque rupture and plaque erosion. A diagnosis of Type 2 MI is based
on evidence of an imbalance between myocardial oxygen supply and




































































































demand unrelated to coronary thrombosis, requiring at least one of the
following: (i) symptoms of acute myocardial ischaemia; (ii) new ischaemic
ECG changes; (iii) development of pathological Q waves; or (iv) imaging
evidence of new loss of viable myocardium or new regional wall motion
abnormality in a pattern consistent with an ischaemic aetiology.
Clinical scenarios of Type 2 MI include severe hypertension, hypoxia,
and tachyarrhythmia. Type 3 MI is the classification used for patients
who suffer cardiac death due to MI, and Types 4 and 5 MI are iatrogenic,
consequent on MI arising from percutaneous coronary intervention
(PCI) or coronary artery bypass graft (CABG), respectively.47 The diag-
nosis of myocardial infarction with no obstructive coronary arteries
(MINOCA) indicates that there is an ischaemic mechanism responsible
for the myocyte injury. Clinical scenarios for MINOCA include MI due
to atherosclerotic plaque rupture, i.e. Type 1 MI, coronary spasm, spon-
taneous coronary dissection, and Type 2 MI.
Myocardial injury is diagnosed based on elevated cardiac biomarkers
without myocardial ischaemia. Acute myocardial injury is associated with
a rise and fall of troponin, whereas chronic myocardial injury is associ-
ated with a stable troponin concentration. Myocardial injury may be pri-
marily due to a cardiac or non-cardiac cause.48 Cardiac causes of
myocardial injury include arrhythmias and disorders of coronary vascular
function. Non-cardiac causes of myocardial injury include anaemia and
pulmonary embolism.48
The plasma concentration of troponin I will be measured using the
Abbott Architect assay. The sex-specific upper reference limits (99th




Cardiovascular magnetic resonance imaging (CMR) is a non-invasive di-
agnostic test for myocardial pathology.49–51 Through tissue characteriza-
tion, CMR can differentiate between myocardial inflammation (acute vs.
chronic), myocardial infarction (acute vs. chronic scar), and pericarditis,
and simultaneously provide information on cardiac function, blood flow,
and incidental findings such as pericardial effusion.49,50,52,53
In COVID-19, myocardial inflammation due to viral myocarditis, ischae-
mia, or stress cardiomyopathy, as well as MINOCA (Type 1 or Type 2 MI)
and other cardiac complications are potentially more common than previ-
ously thought based on current crude biomarker studies. Establishing their
real frequency using powerful imaging techniques is essential for optimizing
risk stratification and therapy. In our study, MRI will be used to assess for
and classify clinical endotypes. The endotypes of myocardial involvement
are (1) myocardial inflammation, e.g. (1.1) myocarditis, (1.2) ischaemia, or
(1.3) stress (Takotsubo) cardiomyopathy; (2) myocardial infarction; (3) in-
determinate; or (4) none. A diagnosis of viral myocarditis typically requires
endomyocardial biopsy (EMB). We do not anticipate that EMB will be un-
dertaken in our study population; therefore, a presumptive diagnosis may
be made based on the available clinical information.
The wide field of view of the chest and abdomen also permits imaging
of the lungs and kidneys.
CT
A computed tomography (CT) coronary angiogram/chest protocol will
image for coronary artery disease (CAD), delayed enhancement, lung
perfusion, pulmonary thrombo-embolism, and parenchymal pathology.
Taken together, integration of multimodality imaging of the heart,
lungs, and kidneys within a single visit represents a highly novel approach
to investigate the cardiovascular complications of COVID-19. The imag-
ing scans will also support advanced computational modelling to better
understand this multisystem disease.
Hypothesis
We hypothesize that myocarditis (myocardial inflammation) is common
after SARS-CoV-2 infection.
Objectives
i. To assess the incidence, nature, time-course and clinical significance of
cardiovascular involvement in patients with COVID-19.
ii. To quantify myocardial perfusion as a measure of coronary microvascu-
lar function.
iii. To determine whether patients with COVID-19 and pre-existing car-
diovascular disease are at increased risk of cardiac involvement.
iv. To assess the incidence of pulmonary thrombo-embolism and right ven-
tricular dysfunction.
v. To assess for renal involvement in patients with COVID-19 and sus-
pected cardiac involvement
vi. To assess mechanisms using circulating biomarkers of cardiac injury [tro-
ponin I, N-terminal probrain natriuretic peptide (NT-proBNP)], inflam-
mation [C-reactive protein (CRP)], vascular injury [sACE2, von
Willebrand factor (vWF), and interleukin-6 (IL-6)], and thrombotic
microangiopathy, and their changes over time.
vii. To establish substudies using computational cardiovascular modelling,
electrocardiography, and pathology.
Study design
The CISCO-19 study has a prospective, observational, multicentre, lon-
gitudinal, cohort design, minimal selection criteria, and a near-
consecutive approach to screening.
Study population
The study population will be focused on COVID-19 patients who have
survived the initial, acute illness. Accordingly, the findings from our study
are most relevant to patients in the convalescent phase looking forward
to the longer term. We will characterize cardiac involvement evidenced
by an increase in circulating high sensitivity troponin I > upper reference
limit at any time during the hospital episode of care. Control data may be
drawn from local cohorts, as appropriate. Patients who received hospital
care with COVID-19 will be enrolled within 28 days of discharge. This
enrolment strategy is intended to maximize enrolment of all-comers af-
fected by COVID-19. Patients who die or are ineligible for other reasons
will be recorded in a screening log.
Multiparametric, stress perfusion, cardiovascular MRI, CT coronary
angiography (CTCA), and a 12-lead ECG will be acquired at 28 days
post-discharge. The study is designed to assess for imaging evidence of
multiorgan injury (Figure 2).
Setting
The study will involve multiple centres in the West of Scotland (popula-
tion 2.2 million) including the Queen Elizabeth University Hospital, the
Royal Infirmary in Glasgow, and the Royal Alexandra Hospital in Paisley.




































..These hospitals provide secondary care services for NHS Greater
Glasgow and Clyde Health Board (Figure 3).
Patient identification
Patients with a diagnosis of COVID-19 will be identified from clinical
databases. The clinical pathways include, but are not limited to: (i)
Emergency Medicine and in-patient wards; and (ii) laboratory records.
Eligibility criteria
The inclusion criteria are: (i) age >18 years old; (ii) history of hospital
attendance or hospitalization for COVID-19, confirmed clinical diagnosis
e.g. case definition according to criteria of the World Health
Organisation and Health Protection Scotland), laboratory test [e.g. poly-
merase chain reaction (PCR)], and/or a radiological test (e.g. CT chest or
chest X-ray); (iii) able to comply with study procedures; and (iv) able
to provide written informed consent. The radiology results will be
reported by accredited radiologists according to contemporary, national
guidelines.
The exclusion criteria are: (i) contra-indication to CMR, e.g. severe
claustrophobia or metallic foreign body; (ii) contra-indication to intrave-
nous adenosine, i.e. severe asthma, long QT syndrome, second- or third-
degree atrioventricular (AV) block, and sick sinus syndrome; and (iii) lack
of informed consent.
Screening
We aim to screen a near-consecutive cohort of patients diagnosed with
COVID-19. A screening log will be prospectively completed. The rea-
sons for being ineligible, including lack of inclusion criteria and/or pres-
ence of exclusion criteria, will be prospectively recorded. This
information will characterize selection bias, if any.
Figure 1 Cardiovascular pathophysiology of COVID-19. With permission of T. Guzik et al. Cardiovascular Research 2020.






















One hundred and eighty patients will be enrolled following
written informed consent. If a consented patient is subsequently
found to be ineligible, unless consent is withdrawn, they will remain
included in the study population, including consent for long-term
follow-up using linkage of electronic government and patient records
(EPRs).
Diagnosis of COVID-19
A diagnosis of COVID-19 will be based either laboratory evidence of
SARS-CoV-2 infection using a PCR test on a biospecimen or a radiologi-
cal diagnosis consistent with COVID-19 but biospecimen negative.54
The laboratory tests used are either the Roche Cobas 6800 or Seegene
SARS-CoV-2 tests.
Figure 3 Primary outcome evaluation.
Figure 2 Schematic study design: flow diagram. The time periods are from hospital discharge. Abbreviations: CTCA, omputed tomography coronary angi-
ography; ECG, electrocardiogram; Q, questionnaires; MRI, stress perfusion cardiac magnetic resonance imaging.





































































































The current protocol involves two visits. The first visit involves informed
consent and baseline assessments. The second visit occurs at 28 days af-
ter discharge. A third visit is intended at 1 year, contingent on additional
funding and a protocol amendment being secured. A proposed vascular
biology substudy involves a gluteal skin biopsy after 28 days. The partici-
pants will be invited to consent for life-long follow-up using electronic
record linkage without direct contact.
The study assessments involve gathering information from standard of
care procedures and research tests. The standard of care information
includes demographics, medical history (including multimorbidity),
limited examination, laboratory and radiological tests, cardiology tests
(including an ECG and an echocardiogram if clinically indicated), and
treatment. The research assessments at both visits include blood and
urine samples, a 12-lead digital ECG (Beneheart R3, Mindray), health sta-
tus questionnaires, and assessments of adverse events. Visit 2 involves
cardiovascular imaging, including stress perfusion MRI and CTCA, and an
ECG. By designating imaging during the convalescent phase, at 28 days
post-discharge, the participants are not anticipated to be infectious.
This approach aligns with other contemporary studies, such as the
International Severe Acute Respiratory and Emerging Infection
Coronavirus Clinical Characterisation Consortium-4 (ISARIC-4C)
study.55 Since MRI and CTCA are appropriately not performed during the
acute phase, some pathologies that might have been detected acutely may
have resolved by 28 days. Therefore, all clinical information obtained dur-
ing Visits 1 and 2 will be used to inform the diagnosis of myocardial injury.
Cardiovascular disease and risk factors
Prior cardiovascular disease includes diabetes, hypertension, myocardial
infarction, heart failure, stroke, and transient ischaemic attack.
Cardiovascular risk factors include age, cigarette smoking, obesity, hy-
pertension, hyperlipidaemia, and glycated haemoglobin. Cardiovascular
risk will be described using the established JBS3 and Heart Age Scores.
Outcomes
Primary outcome
The primary outcome for our study is a diagnosis of myocarditis
(myocardial inflammation). The relevant endotypes are (1) myocardial
inflammation due to (1.1) myocarditis, (1.2) ischaemia, or (1.3) stress
(Takotsubo) cardiomyopathy, (1.4) combination; (2) myocardial infarc-
tion; (3) indeterminate; or (4) none.
Myocardial inflammation is caused by the immune response to virus
infection, autoimmune disease, ischaemic injury, or toxic agents.49 MRI
provides a non-invasive approach to characterizing acute and chronic
myocardial pathology. Expert consensus recommendations for the
CMR-based diagnosis of definite myocardial inflammation include one
T2-based criterion (global or regional increase of myocardial T2 relaxa-
tion time or an increased signal intensity in T2-weighted CMR images),
with at least one T1-based criterion [increased myocardial T1, extracel-
lular volume, or late gadolinium enhancement (LGE)].49,50 Having just
one criterion may support a diagnosis of probable myocardial inflamma-
tion. A key attribute of the imaging protocol in our study involves the pri-
oritized assessment of myocardial perfusion using pharmacological
stress testing with intravenous adenosine. This approach is intended to
permit classification of myocardial injury as being ischaemic or non-
ischaemic, to facilitate classification of myocardial infarction vs. ischaemic
or non-ischaemic myocardial inflammation. Information on myocardial
perfusion will provide insights into coronary microvascular dysfunction
that may, potentially, occur following COVID-19.51 Information from
CTCA will clarify the presence or absence of obstructive CAD and
MINOCA.
Consensus-based diagnosis of the primary outcome
A panel of three or more cardiologists will assess the clinical information
to make a diagnosis (endotype) and related certainty (Not/unlikely = no;
Probable/very = yes) before and after disclosure of the MRI and CTCA
findings. The diagnosis will be based on consensus. This approach reflects
the uncertainty in determining a diagnosis in patients with myocardial in-
jury. The diagnosis draws upon clinical information and test results,
rather than any single test modality in isolation.
Secondary outcomes
A prioritized secondary outcome is the endotype for myocardial injury,
including myocardial infarction type according to the 4th Universal
Definition of MI,47 and myocarditis (myocardial inflammation, ischaemia,
or stress cardiomyopathy).49,50
Patient-reported outcome measures
We aim to assess the impact of cardiovascular complications on health
status, well-being, and physical function. We will prospectively collect
patient-reported outcome measures (PROMS) in order to assess for
associations with the cardiovascular complications of COVID-19,
reflected by the primary and secondary outcomes. Self-reported health
status will be assessed using the generic EuroQOL EQ-5D-5L question-
naire and the Brief Illness Perception Questionnaire (Brief-IPQ).56,57 We
will utilize the Patient Health Questionnaire-4 (PHQ-4) to assess for
anxiety and depressive disorders.58 Participants will be invited to com-
plete these questionnaires at each visit. The Duke Activity Status Index
(DASI) provides a measure of functional capacity, and a higher score
reflects greater physical function.59 The International Physical Activity
Questionnaire–Short Form (IPAQ-SF) measures the types of intensity of
physical activity and time spent sitting that people do as part of their daily
lives. The score reflects total physical activity in MET-min/week and time
spent sitting.60
Biomarkers
In order to research the mechanisms of cardio-pulmonary and renal in-
volvement of SARS-CoV-2 infection, we will measure circulating bio-
markers of inflammation (CRP, ferritin, IL-6), cardiac injury (troponin I,
NT-proBNP), renin–angiotensin system (aldosterone, sACE2), and hae-
mostasis [coagulation screen, Clauss fibrinogen, D-dimer, FVIII (one
stage), VWF antigen and VWF:GP1ba, antithrombin, protein C, and free
protein S)], and renal function (albumin:creatinine ratio) and their
changes over time.
The measurements will be undertaken in a central laboratory, blind
to the other clinical data. The associations between the circulating
concentrations of these mechanistic biomarkers, including their
changes over time, and the primary and secondary outcomes will be
assessed.




































































































Cardio-pulmonary and renal MRI
Cardiovascular MRI is the reference diagnostic method for myocardial
injury, including myocarditis and acute cardiomyopathy. Stress perfusion
MRI using intravenous adenosine enables dynamic imaging of myocardial
blood flow during stress and rest conditions. In-line pixel mapping ena-
bles fully quantitative read-out of myocardial blood flow (mL/min/g tis-
sue), classified at a subsegmental level (32 myocardial segments) with the
percentage extent of myocardium with impaired perfusion during stress
(% ischaemic burden).61–66 All of this information can be spatially
mapped with LV function, tissue characteristics revealed by T2-mapping,
native T-mapping, LGE, and extracellular volume (ECV).52 In this study,
the modified Lake Louise criteria will be used to diagnose definite myo-
cardial inflammation [T2 map þ T1 (native T1, LGE, or ECV abnormal)]
or probable myocardial inflammation (either T2 or T1 abnormal).49,50
In order to limit selection bias, renal dysfunction is not an exclusion crite-
rion. Patients with severe renal dysfunction [glomerular filtration rate
(GFR) <30 mL/kg/m2] will be considered for contrast MRI according to
local radiology protocols.
SARS-CoV-2 causes vascular dysfunction and microthrombotic angi-
opathy.10 Our scientific hypothesis is that microvascular dysfunction
underlies the cardiovascular toxicity caused by this infection through pri-
mary and secondary mechanisms. Direct virus infection of injured endo-
thelial cells, disrupting the integrity of the endothelial barrier, permits
virus infection of deep tissues, causing myocarditis and nephritis.
Myocarditis and ischaemia may induce cardiomyopathy leading to left
and right ventricular dysfunction. Secondary consequences of COVID-
19 including hypoxia, inflammation, and vasospasm impaired tissue perfu-
sion, leading to myocardial ischaemia.
MRI will be undertaken at 3.0 Tesla (Siemens PRISMA)28 days af-
ter discharge. This timepoint may be considered as the subacute, con-
valescent phase. The rationale for undertaking the multiparametric,
stress perfusion cardiovascular MRI at this timepoint is to determine
whether there is persisting evidence of myocardial injury and/or MI,
LV function, and incidental pathology (e.g. mural thrombus) in the
convalescent phase. The patients will be advised to withhold cardio-
vascular medications and to avoid caffeine-containing drinks for 24 h
before the scan.
MRI will also provide information for incidental findings in the chest
(e.g. pulmonary arterial thrombus) and abdomen. Imaging of renal anat-
omy, size, and tissue characterization will be exploratory.
Computed tomography
The CT scanner has 320 detectors enabling full heart coverage within a
single heartbeat (Aquilion ONE, Canon). Intravenous metoprolol will be
used where required to control the heart rate (target 60 b.p.m.) and
sublingual glyceryl trinitrate will be given to all patients immediately
before the scan acquisition. An initial low radiation dose helical scan
of the thorax will be acquired for comprehensive assessment of
the lungs. A contrast bolus timing scan will be acquired which will pro-
vide information on cardiopulmonary transit times. Non-contrast and
contrast-enhanced angiographic breath-hold ECG-gated volumes will be
acquired timed for optimum pulmonary and systemic arterial (coronary)
opacification.
CTCA will provide information on the presence and extent of cor-
onary calcification (calcium score), CAD, and whether CAD is ob-
structive (flow-limiting) including the CAD-RADS score. Intracardiac
thrombus will be assessed. Late enhancement ECG-gated CT will be
acquired to assess for delayed enhancement (scar)67 and ECV calcula-
tion.68 Pulmonary vascular imaging will assess pulmonary vascular
thrombosis (embolism) including CT obstruction score, cardiopulmo-
nary transit times, and measures of raised pulmonary artery (PA) and
right heart pressures [PA, caval and azygous dimensions plus hepatic
inferior vena cava (IVC) reflux]. CT will also characterize pulmonary
features associated with COVID infection (percentage ground-glass
opacity, percentage consolidation, and CO-RADS score) plus pre-
existing lung damage (percentage chronic obstructive pulmonary
.............................................................................................................................................................................................................
Table 1 Secondary outcomes
Secondary outcomes
Health status • Illness perception (Brief IPQ)
• Anxiety/depression (PHQ4)
• EQ-5D-5L
• The Duke Activity Status Index (DASI)
• The International Physical Activity Questionnaire
– Short Form (IPAQ-SF)
• Serious adverse events (SAEs)
Cardiac MRI • Impaired LV systolic function
• Increased LV end-diastolic volume
• Myocardial oedema (T2 map)
• Myocardial inflammation (native T1 map)
• Late gadolinium enhancement
• Increased extracellular volume
• Impaired myocardial perfusion
• Impaired RV systolic function




• Pulmonary artery diameter
• Thrombus, main pulmonary artery
• Microthrombii
Renal • Urine albumin:creatinine ratio
Biomarkers • Circulating biomarkers of inflammation (CRP,
ferritin), cardiac injury (troponin I, NT-proBNP),
vascular injury (aldosterone, sACE2, IL-6) and
haemostasis [coagulation screen, Clauss fibrino-
gen, D-dimer, FVIII (one stage), VWF antigen
and VWF:GP1ba, antithrombin, protein C, and
free protein S)], and renal function
(albumin:creatinine ratio)
Feasibility • Participant withdrawal rate
Exploratory
outcomes
• Vascular biology changes
• Computational modelling of co-registered
imaging to develop novel biomarkers
• ECG abnormalities
• Renal MRI—kidney size, oedema/inflammation,
apparent diffusion coefficient (ADC), a quantita-
tive parameter calculated from diffusion-
weighted imaging (DWI)




































































































disease). CT will also assess for signs of osteoporosis and sarcopenia
as frailty markers.
The CT and MRI findings will be correlated with the other clinical
data. Cardiac and extracardiac findings will be reported and managed
according to local standards of care. Patients with severe renal dysfunc-
tion thought to be at risk of acute kidney injury as determined by local ra-
diology clinical protocols will undergo non-contrast CT.
Natural history
In order to assess the natural history, longer term follow-up for health
outcomes will be undertaken using electronic record linkage, removing
the need for participants to undergo further research visits after the 12-
month visit.
Exploratory analyses
The scans will be pseudoanonymized, i.e. identifiers removed and
assigned a unique study number to enable linkage. The scans will be
shared with research collaborators for cardiovascular modelling to bet-
ter understand the relationships between tissue pathology, blood flow,
and function.
COVID-19 infection and treatment are associated with changes on
the ECG. The changes include alterations in heart rate, conduction, and
ventricular repolarization. Drug treatment for COVID-19 may prolong
the QTc interval. Whether these changes persist after the acute phase
and their relationships to myocardial pathology are unknown. Paper and/
or digital ECGs will be acquired, de-identified, and provided to the
University of Glasgow Electrocardiography Core Laboratory for auto-
mated analysis. The ECG measures will be linked with the clinical and im-
aging data.
We will undertake exploratory research into the vascular biology
of COVID-19 infection. This work will be undertaken in collabora-
tion with cardiovascular scientists and virologists in the University of
Glasgow. We will study the vascular biology of cells and molecules
(e.g. RNA and cytokines) implicated in SARS-CoV-2. Informed
consent will be obtained for post-mortem examination in the event
of death during the study period. Histology samples of the heart will
be examined for features of myocarditis, MI, and microvascular dis-
ease. The histopathological findings will be linked to the CMR
findings.
Feasibility
This study has been developed with input from members of a multidisci-
plinary research team and the Scientific Strategy Group of the University
of Glasgow. The study has been peer reviewed by panel members of the
Chief Scientist Office of the Scottish Government. The study has been
reviewed by the Patient and Public Involvement group of NHS Greater
Glasgow and Clyde Health Board.
Statistical considerations
The statistical analyses will be pre-defined according to a Statistical
Analysis Plan.
Sample size calculation
The primary outcome is myocarditis (myocardial inflammation). To de-
tect an association between a history of pre-existing cardiovascular dis-
ease and the incidence of myocardial inflammation (myocarditis) at 2–4
weeks, we have assumed 25% of patients with prior cardiovascular dis-
ease and the incidence of myocardial inflammation in those with/without
prior cardiac problems to be 33% and 10%, respectively. To have 80%
power to detect this difference will require 140 participants (35 with car-
diac problems, 105 without) to be scanned. We aim for 160 patients to
attend the imaging visit, anticipating that 10–15% of the participants may
have incomplete imaging data due to technical reasons such as imaging
artefact or claustrophobia.
Pre-specified subgroup analyses are intended for patients without car-
diovascular disease, as defined by the absence of (i) prior cardiovascular
disease and (ii) obstructive CAD on CTCA. Given the public health sig-
nificance of COVID-19, interim reports may be undertaken.
Blinding
Outcome assessments (endpoint adjudication) will be undertaken in
blinded fashion. The primary outcome evaluation (myocardial injury
endotype) will be adjudicated by a panel of cardiologists blind to the clin-
ical status of the patient and performed according to a pre-specified
charter.
Trial management and timelines
The trial will be conducted in line with the current Guidelines for Good
Clinical Practice in Clinical Trials and STROBE guidelines.69 The Study
Management Group (SMG) includes those individuals responsible for
the day-to-day management of the study including the chief investigator,
project manager, and representatives from the sponsor. The role of this
group will be to facilitate the progress of the study, ensure that the pro-
tocol is adhered to, and take appropriate action to safeguard participants
and the quality of the study itself. Decisions about continuation or termi-
nation of the study or substantial amendments to the protocol will be
the responsibility of the sponsor. A scientific steering group will oversee
the study. This study is designed to be undertaken and reported rapidly
in response to the global need for information about COVID-19.
Ethics
The CISCO-19 study is approved by the UK National Research Ethics
Service (Reference 20/NS/0066).
Sources of funding
CISCO-19 is an investigator-initiated clinical study that is funded by the
Chief Scientist Office of the Scottish Government (COV/GLA/Portfolio
project number 311300). The funder has no role in the study design,
conduct (non-voting TSC member), data analysis and interpretation,
manuscript writing, or dissemination of the results. C.B, C.D., N.S., R.M.T.
are supported by the British Heart Foundation (BHF RE/18/6134217).
The MRI study involves imaging and analyses technologies provided by
Siemens Healthcare and the National Institutes of Health
The trial is co-sponsored by NHS Greater Glasgow & Clyde and the
University of Glasgow.





































































































The ClinicalTrials.gov identifier is NCT04403607.
Discussion
Our observational, multimodality, imaging cohort study will prospec-
tively gather information on the cardiovascular complications and their
clinical significance in COVID-19. A relatively unselected approach to pa-
tient enrolment will minimize selection bias beyond those who do not
survive or who are unable to comply with the protocol. The findings will
be generalizable to patients in the convalescent phase of the illness and
informative for the natural history. On the other hand, the findings will
not necessarily be generalizable to all patients with COVID-19, since our
enrolment strategy focuses on survivors following the acute phase of the
illness.
Cardiovascular MRI will be used to clarify clinical endotypes according
to contemporary guidelines.49,50 Quantitative measurements of myocar-
dial blood flow at stress and rest will enable focused research into coro-
nary microvascular dysfunction that may be secondary to endotheliitis
caused by SARS-CoV-2. CT imaging will clarify the presence and rele-
vance of CAD and MINOCA, lung pathology, and pulmonary arterial
thrombosis. Renal MRI will be undertaken on an exploratory basis to as-
sess kidney size (differential volume) plus both global values and cortico:-
medullary ratios for T1, T2, and the apparent diffusion coefficient (ADC)
for correlation with renal function. Renal dysfunction is not an exclusion
criterion, reflecting the open approach to enrolment. Taken together
with a comprehensive clinical assessment, laboratory tests (including re-
nal function and urine albumin:creatine ratio), and circulating biomarkers,
our study will characterize multisystem involvement of SARS-CoV-2
infection.
High-sensitivity troponin is a cardiac protein that is ubiquitously re-
leased from injured cardiomyocytes. However, troponin is not cause spe-
cific, and circulating concentrations may increase due to hypoxia,
hypotension, and renal failure, as well from direct cardiac toxicity. It is
unclear whether cardiovascular involvement in COVID-19 is mainly sec-
ondary to severe pneumonia, or whether there is direct viral infection of
the heart and blood vessels. A recent expert consensus guideline
highlighted the pivotal value of CMR in the diagnosis of myocardial inflam-
mation due to viruses, autoimmune disease, ischaemic injury, and toxic
agents. MRI is diagnostically useful to identify endotypes for stratified ther-
apy. We will assess whether this could be the case in COVID-19.
To our knowledge, CISCO-19 is the first to apply stress perfusion
CMR to assess and quantify abnormalities in myocardial perfusion that
may be secondary to microvascular dysfunction. The information on
myocardial perfusion will help classify patients with myocardial injury into
ischaemic or non-ischaemic groups. Stress perfusion MRI is not usually un-
dertaken in patients with myocarditis, and quantitative measurements of
myocardial blood flow are a key attribute of our study design. We aim to
advance new knowledge into the pathogenesis of myocardial inflammation
(ischaemic vs. non-ischaemic) and into the associations between the aetiol-
ogy of disease and abnormalities in myocardial perfusion. Recent advances
in fully quantitative, in-line pixel mapping of myocardial perfusion are
uniquely enabling the quantification of myocardial blood flow in near real-
time without the need for time-intensive, off-line post-processing. In addi-
tion, multimodality imaging involves multiparametric cardiovascular MRI
and CTCA during the same visit. As such, our study will provide methodo-
logically robust estimates of persisting myocardial injury and the impact on
the physical and mental well-being of the participants. The results should
be helpful to inform clinical management strategies for the diagnosis and
management of patients recovering from COVID-19. Our study will pro-
vide complementary information to add to the growing body of knowl-
edge on multisystem involvement in COVID-19.
We will collect information on participants’ characteristics at baseline
including demographics, anthropometry, cardiovascular and medical his-
tory, and health status. The participants will be invited to give informed
consent for life-long follow-up by linkage of EPRs. Using multivariable
analyses, we will link the patients’ characteristics at baseline to observa-
tions during longer term follow-up in order to characterize the natural
history of this condition.
Our imaging research will clarify the prevalence and clinical significance
of cardiopulmonary injury (notably myocardial inflammation) in patients
with COVID-19, which is a major knowledge gap in the NHS. By adopting
an all-comers approach, we will identify patients with myocardial inflam-
mation that is subclinical (i.e. not diagnosed) or clinically overt. By correlat-
ing the MRI findings with troponin and other measures of cardiovascular
injury, such as BNP, our results will potentially inform NHS care pathways
to use these blood tests in a more directed manner for the clinical man-
agement of patients with COVID-19. Currently, there are no disease-
modifying therapies for myocarditis, including due to SARS-CoV-2.
Overall, our study will add new knowledge on the natural history of
COVID-19 in a comparatively unselected population. Our study will cre-
ate a unique biorepository of clinical samples and images, which in turn
may be exploited by scientists undertaking mechanistic research into the
vascular biology of SARS-CoV-2 infection, and cardiovascular modelling.
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M, Püschel K, Kluge S. Autopsy findings and venous thromboembolism in patients
with COVID-19: a prospective cohort study. Ann Intern Med 2020;doi:
10.7326/M20-2003.
38. Puelles VG, Lütgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L,
Chilla S, Heinemann A, Wanner N, Liu S, Braun F, Lu S, Pfefferle S, Schröder AS,
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